Cancer docs push HPV vaccine; GSK says experimental lung combo trumps Symbicort; Google rolls out new symptom search feature
FDA leader says drugmakers should develop more novel drugs; Merck to acquire Afferent for $1.25 billion; Colombia demands lower prices for Gleevec
Bing can identify people with cancer symptoms; an experimental rheumatoid arthritis meets trial goals; the FDA updates compassionate use rules
Investors said a combination of Opdivo and Yervoy is the top-performing regimen in a niche of non-small cell lung-cancer patients.
Researchers question cost of multiple-myeloma combo; drugmakers say CAR-T therapies will soon be approved; the FDA approves Allergan's hypertension drug
Here, see side-by-side comparisons of the drugs spending on advertising, approval dates, and 2015 sales figures.
Keytruda's survival benefit is reinforced by new study; drugmakers reference patient-assistance programs in debate over drug prices; China cuts drug prices
Opdivo nets new indication; government to view Humira patent; AstraZeneca's asthma drug expected to be filed this year
Novartis breaks up pharmaceutical division and announces that David Epstein, CEO of Novartis Pharmaceuticals, will leave the company.
Using a med-tech strategy may help stem concern about CAR T-cell technology's complicated distribution and anticipated high prices, said Novartis exec.
The loss of patent exclusivity for cancer drug Gleevec contributed to a 12% sales drop, but the drugmaker expects sales from Entresto and Cosentyx to pick up the slack.
Immuno-oncology drugs showing results in hard-to-treat cancers; Express Scripts responds to Anthem lawsuit; BI and Lilly plan outcomes trials for Jardiance
IBM Watson Health's cognitive computing system for oncology tackles one of the leading causes of death worldwide and attempts to eradicate misdiagnoses.
Some 30% of the physicians in the U.S. sold their practices, which in turn commensurately reduced the number of physicians who are willing and able to be called on by sales reps.
The drugmaker instead suggested using an economic model it developed.
The scientific services company expands its portfolio to include expertise in oncology clinical studies.
The regulator's reliance on double-blind, placebo-controlled trials with exhaustive inclusion and exclusion criteria is incompatible with today's precision medicine.
Manufacturers team up to study drug combinations, a strategy expected to advance the category.
Bristol-Myers Squibb considered immunotherapy market leader; McKesson buys two cancer-care companies; Bayer names new CEO
Cancer MoonShot 2020 to study childhood cancers; IBM's purchase of Truven provides data about 200 million patients; overdoses tied to benzodiazepines rise
Health economic and outcomes research datasets have rarely been integral to product development and communication plans.
Biden to lead "moonshot" to cure cancer; Pfizer/Allergan merger to create "best pipeline in the industry," CEO says; AMA invests in health tech startup
The drugmaker led a Series C fundraising round totaling $175 million. The funding will be used to accelerate clinical trials.
Twenty percent of publicly funded cancer clinical trials don't enroll enough patients; KaloBios files for bankruptcy; a new MS campaign in Australia uses bicycles
David Meek has been charged with building an oncology arm that matches the company's existing strengths in hematology and immunology.
Britain says Bristol-Myers Squibb's Opdivo is too expensive; Calpers reports 32% boost in specialty drug spending; NIH is funding fewer clinical trials
Physicians complain about price of Lilly's new cancer drug; AstraZeneca considers acquisition of Acerta Pharma; Shkreli plans to raise price of another old drug
Pfizer reveals Ibrance pricing strategy; AMA call for DTC ban may resonate due to pricing debate; Baxalta's Vonvendi receives FDA approval
AstraZeneca plans to incorporate a mobile app that gathers information about side effects in three clinical trials studying an experimental combination therapy for ovarian cancer.
FDA advisers vote against BioMarin's Duchenne drug; the FDA approves Lilly's lung-cancer drug; criticism mounts for Pfizer's proposed deal with Allergan
- No free lunch for docs: Sponsored meals linked to more prescriptions
- Allergan draws on A-list celebs to drive engagement
- Non-profit behind 'Free Killer Tan' wants parents to practice sun safety
- Five things for pharma marketers to know: Monday, June 20, 2016
- Galderma exec: Skip the market research (sometimes)